...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >High-Dose IL-2 Skews a Glucocorticoid-Driven IL-17(+)IL-10(+) Memory CD4(+) T Cell Response towards a Single IL-10-Producing Phenotype
【24h】

High-Dose IL-2 Skews a Glucocorticoid-Driven IL-17(+)IL-10(+) Memory CD4(+) T Cell Response towards a Single IL-10-Producing Phenotype

机译:高剂量IL-2倾斜糖皮质激素驱动的IL-17(+)IL-10(+)内存CD4(+)T细胞响应单il-10产生表型

获取原文
获取原文并翻译 | 示例

摘要

Glucocorticoids are known to increase production of the anti-inflammatory cytokine IL-10, and this action is associated with their clinical efficacy in asthmatics. However, glucocorticoids also enhance the synthesis of IL-17A by PBMCs, which, in excess, is associated with increased asthma severity and glucocorticoid-refractory disease. In this study, we show that the glucocorticoid dexamethasone significantly increased IL-10 production by human memory CD4(+) T cells from healthy donors, as assessed by intracellular cytokine staining. In addition, dexamethasone increased production of IL-17A, IL-17F, and IL-22, with the most striking enhancement in cells coproducing Th17-associated cytokines together with IL-10. Of note, an increase in IFN-gamma+IL-10(+) cells was also observed despite overall downregulation of IFN-gamma production. These dexamethasone-driven IL-10(+) cells, and predominantly the IL-17(+)IL-10(+) double-producing cells, were markedly refractory to the inhibitory effect of dexamethasone on proliferation and IL-2R alpha expression, which facilitated their preferential IL-2-dependent expansion. Although lower concentrations of exogenous IL-2 promoted IL-10(+) cells coproducing proinflammatory cytokines, higher IL-2 doses, both alone and in combination with dexamethasone, increased the proportion of single IL-10(+) T cells. Thus, glucocorticoid-induced IL-10 is only accompanied by an increase of IL-17 in a low IL-2 setting, which is, nevertheless, likely to be protective owing to the induction of regulatory IL-17(+)IL-10(+)-coproducing cells. These findings open new avenues of investigation with respect to the role of IL-2 in glucocorticoid responsiveness that have potential implications for optimizing the benefit/risk ratio of glucocorticoids in the clinic.
机译:糖皮质激素是已知的提高产量的抗炎细胞因子IL-10的,并且该动作是与他们的临床疗效哮喘相关联。但是,糖皮质激素也由PBMC中,其在过量,与增加的哮喘的严重程度和糖皮质激素难治性疾病相关联的提高的IL-17A的合成。在这项研究中,我们表明,糖皮质激素地塞米松显著增加IL-10的产生受到人类记忆CD4(+)T细胞来自健康供体,通过细胞内细胞因子染色评价。此外,地塞米松增加的生产IL-17A,IL-17F和IL-22的,在细胞与IL-10的Th17联产相关的细胞因子一起的最显着的提高。的音符,增加的IFN-γ+ IL-10也被尽管IFN-γ生成的整体观察到下调(+)细胞。这些地塞米松驱动IL-10(+)细胞和主要的IL-17(+)IL-10(+)双产生细胞,均显着耐火到地塞米松的抑制作用对增殖和IL-2Rα表达,这有利于它们的优惠IL-2依赖性扩张。虽然外源IL-2的较低浓度的促进IL-10(+)细胞联产促炎细胞因子,更高的IL-2的剂量,单独和与地塞米松组合,增加了单IL-10(+)T细胞的比例。因此,糖皮质激素诱导的IL-10仅伴随着在低IL-2的设定,这一点,但增加了IL-17的,容易保护由于调控IL-17(+)的诱导是IL-10 (+) - 联产细胞。这些发现开辟新的研究途径相对于IL-2的糖皮质激素的反应有在临床优化糖皮质激素的效益/风险比潜在的影响作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号